[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606191":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":11,"centralContacts":32,"locations":38,"responsibleParty":58,"collaborators":11,"id":60,"slug":11,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":11,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":11,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":11,"overallStatus":41,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Jiangsu vcare pharmaceutical technology co., LTD","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"VC005 Tablets Low Dose groups","EXPERIMENTAL",null,[13],"Drug: VC005 tablets",{"label":15,"type":10,"description":11,"interventionNames":16},"VC005 Tablets High Dose groups",[13],{"label":18,"type":19,"description":11,"interventionNames":20},"VC005 Tablets Placebo groups","PLACEBO_COMPARATOR",[21],"Drug: VC005 Tablets Placebo",[23,28],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"DRUG","VC005 tablets","VC005 groups repeat administration for 52 weeks",[15,9],{"type":24,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"VC005 Tablets Placebo","VC005 Placebo groups repeat administration for 52 weeks",[18],[33],{"name":34,"role":35,"phone":36,"phoneExt":11,"email":37},"xiaojuan lai","CONTACT","15358160458","lai_xiaojuan@vcarepharmatech.com",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":11,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"The Peking University People's Hospital","RECRUITING","Beijing","Beijng","China",{"type":46,"coordinates":47},"Point",[48,49],116.39723,39.9075,{"lat":49,"lon":48},[52,56],{"name":53,"role":35,"phone":54,"phoneExt":11,"email":55},"Jianzhong Zhang","010-88325471","rmzjz@126.com",{"name":53,"role":57,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"type":59,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100606191",false,"NCT07172347","Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo","A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Non-segmental Vitiligo","Inclusion Criteria:\n\n* The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol.\n* The subject is between 18 and 70 years of age (including borderline values) , regardless of gender.\n\nExclusion Criteria:\n\n* Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.\n* All hair in the vitiligo area on the face is white.\n* Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs.\n* Subjects who have previously received depigmentation treatment.\n* Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.","ALL","18 Years","75 Years",{"count":70,"type":71},120,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study",[77],"Non-segmental Vitiligo","2025-12-29",{"date":80,"type":81},"2026-01-02","ACTUAL",{"date":83,"type":81},"2025-10-31",{"date":85,"type":71},"2027-08-30",{"name":5,"class":6},1]